Participants
Cancer, peripheral neuropathy, pain
BREAST CANCER, METASTATIC DISEASE, MAY, PERIPHERAL NEUROPATHY, CANCER
We consented to participants from May 2015 to March 2017 as part of screening in a phase IIA trial of weekly acupuncture intervention in women with early-stage breast cancer.We excluded participants with known metastatic disease; pre-existing peripheral neuropathy within 28 days of screening consent; or current use of anti-neuropathic pain agents including gabapentin, pregabalin, duloxetine, or glutamine. Informed consent was obtained from all participants prior to enrollment. The study was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (ClinicalTrial.gov identifier NCT02364726) and we previously reported the primary outcome.